α-1-antichymotrypsin polymorphism in the gene promoter region affects survival and synapsis loss in Alzheimer's disease

Archives of Gerontology and Geriatrics

Volumn 38, Issue SUPPL., 2004, Pages 243-251

  Licastro, F ^a   Chiappelli, M ^a   Thal, L J ^b   Masliah, E ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease progression and pathology; APOE and ACT gene

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; PROTEIN SUBUNIT; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ALPHA 1 ANTITRYPSIN; SERPINA1 PROTEIN, HUMAN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; DEATH; DISEASE COURSE; DISEASE DURATION; FEMALE; FRONTAL CORTEX; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; NERVE CELL PLASTICITY; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL; BRAIN; GENE EXPRESSION; GENETICS; MORTALITY; NERVE DEGENERATION; PATHOLOGY; SURVIVAL RATE; SYNAPSE;

AGED; AGED, 80 AND OVER; ALLELES; ALPHA 1-ANTITRYPSIN; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; MALE; NERVE DEGENERATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); SURVIVAL RATE; SYNAPSES; SYNAPTOPHYSIN;

EID: 3042681039     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2004.04.034     Document Type: Article

References (28)

1. Abraham, C.R., Shirahama, T. and Potter, H. (1990): α-1- antichymotrypsin is associated solely with amyloid deposits containing the b-protein. Amyloid and cell localization of α-1-anti-chymotrypsin. Neurobiol. Aging, 11, 123-129.
2. Alford, M.F., Masliah, E., Hansen, L.A. and Terry, R.A. (1994): A simple dot imrnunobinding assay for quantification of synaptophysin like immunoreactivity in human brain. J. Histo-chem. Cytochem., 42, 283-287.
3. APA (American Psychiatric Association) (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. APA Press, Washington, D.C.
4. Armstrong, R.A., Nochlin, D. and Bird, T.D. (2000): Neuropathological heterogeneity in Alzhei-mer's disease: a study of 80 cases using principal components analysis. Neuropathology, 20, 31-37.
5. Beach, T.G., Walzer, R. and McGeer, E.G. (1989): Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia, 2, 420-436.
6. Breitner, J.C.S., Gau, B.A., Welsh, K.A., Plassman, B., McDonald, W.M., Helms, M.J. and Antony, J.C. (1994): Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology, 44.227-232.
7. Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schemechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L. and Pericak-Vance, M.A. (1993): Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921-923.
8. Corey-Bloom, J., Tiraboschi, P., Hansen, L.A., Alford, M., Schoocs, B., Sabbagh, M.N., Mas-liah, E. and Thal, L.J. (2000): E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology, 54, 403-406.
9. Grimaldi, L.M.E., Casadei, V.M., Ferri, C., Veglia, F., Licastro, F., Annoni, G., Biunno, I ., DeBellis, G., Sorbi, S., Mariani, C., Canal, N., Griffin, W.S.T. and Franceschi, M. (2000): Association of early onset Alzheimer's disease with an interleukin-1á gene polymorphism. Ann. Neurol., 47, 351-365.
10. Henderson, AS. (1986): The epidemiology of Alzheimer's disease. Br. Med. Bull., 42, 3-10.
11. Licastro, F., Campbell, I.L., Kinkaid, C., Veinbergs, I., Van Uden, E., Rockstein, E., Mallory, M., Gilbert, J.R. and Masliah, E. (1999a): A role for apoE in regulating the levels of á-1-anti-chymotrypsin in the aging mouse brain and in Alzheimer's disease. Am. J. Pathol., 155, 869-875.
12. Licastro, F., Pedrini, S., Govoni, M., Pession, A., Ferri, C., Annoni, G., Casadei, V., Veglia, F., Bertolini, S. and Grimaldi, L.M.E. (1999b): Apolipoprotein E and á-1-antichy-motrypsin allele polymorphism in sporadic and familial Alzheimer's disease. Neurosci. Letters, 270, 129-132.
13. Licastro, F., Pedrini, S., Casadei, V., Govoni, M., Pession, A., Sciacca, F.L., Veglia, F., Annoni, G., Bonafè, M., Olivieri, F., Franceschi. C. and Grimaldi, L.M.E. (2000): Gene polymorphism affecting a-1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neurol., 48, 388-391.
14. Licastro, F., Veglia, F., Chiappelli, M., Grimaldi, L.M.E. and Masliah, E. (2004): Polymorphism of the interleukin-1-gene influences progression and neuropathological hallmarks of Alzheimer's disease. Neurobiol. Aging, (in press).
15. Luterman, J.D., Harountnian, V., Yemul, S., Ho, L., Purohit, D., Aisen, P.S., Mohs, R. and Pasinetti, G.M. (2000): Cytokine gene expression as function of the clinical progression of Alzheimer disease dementia. Arch. Neurol., 57, 1153-1160.
16. Masliah, E., Mallory, M., Alford, M.F., Deteresa, R., Hansen, L.A., McKeel, D.W. and Morrison, J,C. (2001): Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56, 127-129.
17. McGeer, E.G. and McGeer, P.L. (1998): The importance of inflammatory mechanisms in Alzheimer's disease. Exp. Gerontol., 33, 371-378.
18. McGeer, P.L., Schulzer, M. and McGeer, E.G. (1996): Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's diseases: a review of 17 epidemiological studies. Neurology, 47, 425-432.
19. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M. (1984): Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Departement of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34,939-944.
20. Meyner, M R., Tschanz, J.T., Norton, M.C., Welsh-Bohmer, K.A., Steffens, D.C., Wyse, B.W. and Breitner, J.C.S. (1998): APOE genotype predicts when-not whether-one is predisposed to develop Alzheimer's disease. Nature Genetics, 19, 321-322.
21. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.T., Brownlee, L.M., Vogel, F.S., Hughes, J.P., Van Bellem G. and Berg, L. (1991): The consortium to establish a registry for Alzheimer's disease. Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 41, 497-486.
22. Miyakawa, T., Shimoji, A., Kuramoto, R. and Higuchi, Y. (1982): The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol., 40, 121-129.
23. Morgan, K., Licastro, F., Tilley, L., Ritchie, A., Morgan, L., Pedrini, S. and Kalsheker, N. (2001): Polymorphism in the alpha 1-antichymotripsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum. Genet., 109, 303-310.
24. Mrak, R.E., Sheng, J.G. and Griffin, S.T. (1995): Glial cytokines in Alzheimer's disease: review and pathogenetic implications. Human Pathol., 26, 816-823.
25. Mucke, L., Yu, G.Q., McConlogue, L., Rockstein, E.M., Abraham, C.R. and Maslah, E. (2000): Astroglial expression of human alpha(1)-antichymotrypsin enhances Alzheimer's like pa-thology in amyloid protein precursor transgenic mice. Am. J. Pathol., 157, 2003-2010.
26. Murphy, G.M. Jr., Taylor, J., Kraemer, H.C., Yesavage, J. and Tinklenberg, J.R. (1997): No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am. J. Psychiatry, 154, 603-608.
27. Rubinsztein, D.C. (1997): The genetics of Alzheimer's disease. Progr. Neurobiol., 52, 447-454.
28. Soininen, H.S. and Riekkinen, P.J. (1996): Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci., 19. 224-228.